Castle Biosciences Announces Third Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Castle Biosciences Inc. (CSTL) Misses Q3 EPS by 12c
November 9, 2020 4:57 PM ESTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q3 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $14.99 million.
The Castle team made significant progress on our strategic growth initiatives in the third quarter, said Derek Maetzold, president and chief executive officer of Castle Biosciences. We also returned to year-over-year volume growth in DecisionDx®-Melanoma report volume, our current lead revenue driver, despite a... More
